Genetic progression in gastrointestinal stromal tumors: mechanisms and molecular interventions

Citations Over TimeTop 15% of 2017 papers

Abstract

// Ke Li 1,2* , Haibo Cheng 4,5,6* , Zhang Li 1,2 , Yuzhi Pang 1,2 , Xiaona Jia 1,2 , Feifei Xie 1,2 , Guohong Hu 2 , Qingping Cai 7 and Yuexiang Wang 1,2,3 1 SIBS (Institute of Health Sciences), Changzheng Hospital Joint Center for Translational Medicine, Institute of Health Sciences, Shanghai Changzheng Hospital, Institutes for Translational Medicine (CAS-SMMU), University of Chinese Academy of Sciences, Shanghai, China 2 Key Laboratory of Stem Cell Biology, Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and Shanghai Jiao Tong University School of Medicine, Shanghai, China. 3 Collaborative Innovation Center of Systems Biomedicine, Shanghai Jiao Tong University School of Medicine, Shanghai, China 4 The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China. 5 Key Laboratory of SATCM for Empirical Formulae Evaluation and Achievements Transformation, Nanjing, China. 6 Collaborative Innovation Center of Jiangsu Province Chinese Medicine in Cancer Prevention and Treatment, Nanjing, China 7 Department of Gastro-intestinal Surgery, Changzheng Hospital, Second Military Medical University, Shanghai, China * These authors have contributed equally to this work Correspondence to: Yuexiang Wang, email: // Qingping Cai, email: // Keywords : gastrointestinal stromal tumors, dystrophin, small molecules, targeted therapy Received : January 25, 2017 Accepted : March 02, 2017 Published : March 08, 2017 Abstract Gastrointestinal stromal tumors (GISTs) are the most common sarcomas in humans. Constitutively activating mutations in the KIT or PDGFRA receptor tyrosine kinases are the initiating oncogenic events. Most metastatic GISTs respond dramatically to therapies with KIT/PDGFRA inhibitors. Asymptomatic and mitotically-inactive KIT/PDGFRA-mutant “microGISTs” are found in one third of adults, but most of these small tumors never progress to malignancy, underscoring that a progression of oncogenic mutations is required. Recent studies have identified key genomic abnormalities in GIST progression. Novel insights into the genetic pro­gression of GISTs are shedding new light on thera­peutic innovations.

Related Papers

• → Prevalence, clinico-pathological value, and co-occurrence of PDGFRA abnormalities in diffuse gliomas(2012)72 cited
• → Malignant Gliomas: Role of Platelet-Derived Growth Factor Receptor A (PDGFRA)(2010)6 cited
• → Functional evaluation of the patient-derived iPS cells from <i>PDGFB</i>-variants in idiopathic basal ganglia calcification(2020)
• → Data from Platelet-Specific PDGFB Ablation Impairs Tumor Vessel Integrity and Promotes Metastasis(2023)
• → #415 Angiogenetic factors predict clinical outcome in endometrial cancer(2023)